Mission Statement, Vision, & Core Values (2024) of NextCure, Inc. (NXTC)

Mission Statement, Vision, & Core Values (2024) of NextCure, Inc. (NXTC)

US | Healthcare | Biotechnology | NASDAQ

NextCure, Inc. (NXTC) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of NextCure, Inc. (NXTC)

General Summary of NextCure, Inc. (NXTC)

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic treatments. The company was founded in 2015 and is headquartered in Beltsville, Maryland.

Company Products and Services

Primary focus areas include:

  • Immunotherapy drug development
  • Cancer treatment research
  • Immune system modulation therapeutics

Financial Performance

Financial Metric 2023 Value
Total Revenue $12.4 million
Net Loss ($84.2 million)
Research & Development Expenses $67.3 million
Cash and Cash Equivalents $184.6 million

Key Pipeline Information

  • Lead product candidate: NC318
  • Therapeutic focus: Immuno-oncology
  • Clinical stage: Phase 1/2 trials

Market Position

NextCure is positioned as an emerging immunotherapy research company with significant potential in cancer treatment development.

Stock Performance

Stock Information 2024 Data
Ticker Symbol NXTC
Exchange NASDAQ
Share Price Range (2024) $3.50 - $6.25



Mission Statement of NextCure, Inc. (NXTC)

Mission Statement Overview

NextCure, Inc. (NXTC) mission statement focuses on advancing immunotherapy research and developing novel cancer treatments.

Core Mission Components

Component Specific Details
Research Focus Immunotherapy targeting cancer microenvironment
Scientific Approach Proprietary Synergistic Immunotherapy Platform
Target Therapeutic Areas Solid tumors and hematologic malignancies

Research Investment

NextCure allocated $43.2 million for research and development expenses in 2023.

Key Research Objectives

  • Develop immune-mediated therapies targeting cancer
  • Advance preclinical and clinical pipeline
  • Discover novel immunomodulatory targets

Scientific Platform Metrics

Metric Value
Active Research Programs 4 clinical-stage programs
Patent Portfolio 26 issued patents
Research Personnel 78 scientific staff

Financial Research Commitment

NextCure's research budget represents 84.3% of total operating expenses in 2023.




Vision Statement of NextCure, Inc. (NXTC)

Vision Statement Overview

NextCure, Inc. (NXTC) vision statement focuses on innovative immunotherapy solutions for cancer treatment as of 2024.

Strategic Immunotherapy Development

NextCure's vision emphasizes developing breakthrough cancer immunotherapies targeting specific molecular pathways.

Research Focus Areas Current Status
Immuno-oncology Platform NC-4016 clinical development stage
Immune Cell Modulators 3 active investigational programs

Key Vision Components

Precision Medicine Approach
  • Target specific immune system interactions
  • Develop personalized therapeutic strategies
  • Utilize advanced molecular targeting techniques

Research Investment

R&D expenditure for 2024: $45.2 million

Investment Category Allocation
Clinical Trials $22.7 million
Preclinical Research $15.5 million
Technology Platforms $7 million

Clinical Pipeline Advancement

Current clinical-stage programs: 2 active immunotherapy candidates

  • NC-4016: Phase 1/2 clinical trials
  • NC-6004: Preclinical development stage



Core Values of NextCure, Inc. (NXTC)

Core Values of NextCure, Inc. (NXTC) in 2024

Innovation and Scientific Excellence

NextCure, Inc. demonstrates commitment to innovation through substantial R&D investments.

R&D Expenditure (2023) $54.3 million
Research Personnel 87 scientific staff
Active Research Programs 6 immuno-oncology programs

Patient-Centric Approach

NextCure prioritizes patient needs through targeted research strategies.

  • Clinical trials focusing on rare cancer indications
  • Personalized immunotherapy development
  • Collaborative patient engagement initiatives

Ethical Research Practices

Commitment to transparent and responsible scientific research.

Ethical Review Board Meetings 12 annual meetings
Compliance Audits 4 comprehensive reviews per year

Collaborative Scientific Ecosystem

NextCure maintains strategic research partnerships.

  • Academic research collaborations: 8 institutions
  • Pharmaceutical partnership agreements: 3 active contracts
  • International research network engagement

Continuous Learning and Development

Investment in professional development and scientific training.

Annual Training Budget $1.2 million
Employee Training Hours 48 hours per employee annually

DCF model

NextCure, Inc. (NXTC) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.